MHC-HM412T-100μg / 询价
MHC-HM412T-500μg / 询价
MHC-HM412T-500μgx2 / 询价
- 客服电话
- 技术支持
Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer Protein
Recombinant Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin.It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and LMLGEFLKL peptide [Accession | A0A140T913(HLA-A*02:01)&P61769(B2M)&LMLGEFLKL].
The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per ug by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.
The purity of Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer is greater than 95% as determined by SEC-HPLC.
Immobilized Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 9.5ng/ml determined by ELISA (QC Test).
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target.
Survivin; MHC; MHC I; BIRC5; API4; EPR-1; IAP4; survivin variant 3 alpha
(1) Wheatley SP, Altieri DC. Survivin at a glance. J Cell Sci. 2019 Apr 4;132(7):jcs223826. doi: 10.1242/jcs.223826. PMID: 30948431; PMCID: PMC6467487.
